Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (417)	4/13/2001 1:14:04 PM
From: scaram(o)uche	Respond to of 2243

>> Tough to answer. Personal admiration for two members of the management team who are now history or near history, but who have nonetheless guided a company that is known for not having been forthcoming. Certain issues with formulation and nephrotoxicity have either been candy coated and/or semi-withheld from shareholders. I feel that Rurka honestly believed that one of several irons in fire would have productively matured in a timely fashion, and that his attempt to gild all "balls in air" is a disease of old-time biotech managers. << Was just contacted by a friend of MCDE. Some of his commentary was picked up by someone and posted at Yahoo, out of the "critical" context of this thread. People with slimeball agendas...... wish they wouldn't quote without asking for further details or context. I believe that the managers and scientists at Microcide are sincere and honest as heck. It's unfortunate that milestones have fallen aside. It's tough, competitive science, and partners don't always move according to your recipe. The nephrotoxicity....... only observed in preclinical testing. It hasn't been widely discussed because it hasn't been an issue in human trials. A second generation molecule is contrasted as having lower toxicity in preclinical testing, and that's the context that I should have painted. Solubility issues (formulation issues)...... I shouldn't have used the term "candy coated". The fact is that milestone after milestone for this project (i.v. cephalosporin) has been missed. In that sense..... the sense that objectives have been presented as near-term and have thereafter not been met...... the obstacles to success have been inadvertantly candy-coated, IMO. I like the company. I like management. I wish that Jim Rurka could have found immense success as CEO. I feel that MCDE has tremendous potential for growth and innovation. I'm frequently asked to comment about companies. In this case, I was asked to comment in the context of a small capitalization. I therefore tried to give some feel for why the company has arrived at this tough place..... good science in need of financing. I really don't appreciate some anon jerk at Yahoo having transplanted my comments in an attempt to manipulate public opinion of this superbly ethical organization. To that anon Yahoo jerk, Wallbangee...... my opinion, overall? Class, under-valued research organization, and I just recently added MCDE to portfolio "2000". You didn't point that last part out at Yahoo, did you? I'm really sorry that I provided ammunition for your agenda.